ADVERTISEMENT

Study offers reassurance to postmenopausal women taking hormone therapy

The Journal of Family Practice. 2020 October;69(8):audio
September 22, 2020|Family Medicine
Doug Campos-Outcalt, MD, MPA
Author and Disclosure Information

Doug Campos-Outcalt, MD, MPA, is a clinical professor at the University of Arizona College of Medicine, a senior lecturer with the University of Arizona College of Public Health, and a member of the US Community Preventive Services Task Force. He’s also an assistant editor at The Journal of Family Practice.

The speaker reported no potential conflict of interest relevant to this audiocast.

This month, Dr. Campos-Outcalt summarizes findings from a long-term follow-up study of Women’s Health Initiative participants that offers reassurance for women who use hormone therapy to relieve postmenopausal symptoms. He also describes how the study’s findings lend further support to a US Preventive Services Task Force recommendation against using hormone therapy for the prevention of chronic conditions.

References 

  1. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;32:369-380.
  2. The North American Menopause Society. Menopause Guidebook. 8th ed. www.menopause.org/publications/consumer-publications/-em-menopause-guidebook-em-8th-edition. Accessed September 25, 2020.
  3. US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;318:2224-2233.

,false
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT